fluorodeoxyglucose f18 has been researched along with psma-617 in 4 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (25.00) | 24.3611 |
| 2020's | 3 (75.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bakshi, G; Banerjee, S; Basu, S; Joshi, A; Parghane, RV; Prabhash, K; Suman, S; Talole, S | 1 |
| Burkett, BJ | 1 |
| Azad, AA; Buteau, JP; Davis, ID; Emmett, L; Francis, RJ; Hofman, MS; Iravani, A; Joshua, AM; Lee, ST; Martin, AJ; McJannett, MM; Sandhu, S; Scott, AM; Stockler, MR; Williams, SG; Zhang, AY | 1 |
| Akdogan, B; Aksoy, S; Caglar, M; Erman, M; Karabulut, E; Telli, T; Tuncel, M | 1 |
1 trial(s) available for fluorodeoxyglucose f18 and psma-617
| Article | Year |
|---|---|
PSMA and FDG-PET as predictive and prognostic biomarkers in patients given [
Topics: Adolescent; Adult; Australia; Fluorodeoxyglucose F18; Humans; Male; Prognosis; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Treatment Outcome | 2022 |
3 other study(ies) available for fluorodeoxyglucose f18 and psma-617
| Article | Year |
|---|---|
Therapeutic efficacy, prognostic variables and clinical outcome of
Topics: Aged; Aged, 80 and over; Antigens, Surface; Dipeptides; Fluorodeoxyglucose F18; Gallium Radioisotopes; Glutamate Carboxypeptidase II; Heterocyclic Compounds, 1-Ring; Humans; Lutetium; Male; Middle Aged; Molecular Targeted Therapy; Neoplasm Grading; Positron Emission Tomography Computed Tomography; Prognosis; Progression-Free Survival; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Quality of Life; Radioisotopes; Radiopharmaceuticals; Retrospective Studies; Treatment Outcome | 2019 |
LuPIN Substudy of Posttreatment PET after
Topics: Dipeptides; Fluorodeoxyglucose F18; Heterocyclic Compounds, 1-Ring; Humans; Positron-Emission Tomography; Prognosis; Prostate-Specific Antigen | 2022 |
Prognostic factors of overall and prostate-specific antigen-progression-free survival in metastatic castration-resistant prostate cancer patients treated with
Topics: Fluorodeoxyglucose F18; Humans; Male; Positron Emission Tomography Computed Tomography; Prognosis; Progression-Free Survival; Prospective Studies; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Treatment Outcome | 2023 |